Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Catalent Inc    CTLT

CATALENT INC

(CTLT)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Catalent : to double biomanufacturing capacity with $200m investment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 04:39am EDT

Catalent will use the funds to enlarge drug substance manufacturing and drug product fill/finish capacity.

The $200m (173m) investment will take place at Catalents biologics manufacturing sites in Madison, Wisconsin, and Bloomington, Indiana. The decision follows the expansion of its biologics packaging capacity, at the latter site.

The improvement upon current capacity in drug substance manufacturing and fill/finish will take place over three years.

It will see mammalian cell culture capacity increased with two new suites, each housing a two 2,000 litre single-use bioreactor system. Fill/finish capacity will be increased by an expanded Bloomington site, which will grow by 79,000-sq-ft to accommodate a high-speed flexible vial line operating at 300 units per minute.

Brian Riley, VP of operations, biologics and specialty drug delivery at Catalent, told us that the expansion is required to meet increasing demand in the late-stage clinical and commercial supply phases.

The Bloomington facility recently achieved regulatory approval for a twentieth commercial product, so part of the expansion at both sites is necessary to fulfil increasing demand from existing customers programs, but the expansion is also in anticipation of new business too, Riley explained.

The upgrade to both facilities will also add new staff members over the coming years. Riley could not specify a precise number but said, we anticipate adding over 100 new roles in Madison, and up to 200 new jobs in Bloomington by the end of 2024.

Catalent acquired the Bloomington facility as part of its $950m takeover of Cook Pharmica in 2017. Subsequently, the company revealed that it would be looking to the site, with it operating at 45% of its capacity upon acquisition.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CATALENT INC
08:38aCATALENT : Advances in Biologics Development to be Discussed at Symposium Hosted..
AQ
03/19CATALENT : Advances in Biologics Development Hosted by the Catalent Applied Drug..
AQ
03/19CATALENT : Advances in Biologics Development Hosted by CADDI
PU
03/12CATALENT : Techniques for Achieving High Dose Accuracy to be Presented by Catale..
AQ
03/12CATALENT : Biologics Experts at ISPE Aseptic Conference
PU
03/08CATALENT : Invests Over $27 Million to Commercialize Zydis Ultra, a Next Generat..
AQ
03/06CATALENT, INC. : to Present at the Barclays Global Healthcare Conference
BU
03/05CATALENT : Experts to Present at CTS Europe and CTS New England
PU
02/28CATALENT : CADDI and Northeastern University to Host Symposium
PU
02/22CATALENT : Appoints Kay Schmidt to Executive Leadership Team to Lead New Technic..
AQ
More news
Financials ($)
Sales 2019 2 533 M
EBIT 2019 410 M
Net income 2019 163 M
Debt 2019 1 765 M
Yield 2019 -
P/E ratio 2019 42,31
P/E ratio 2020 31,84
EV / Sales 2019 3,15x
EV / Sales 2020 2,90x
Capitalization 6 214 M
Chart CATALENT INC
Duration : Period :
Catalent Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CATALENT INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 45,8 $
Spread / Average Target 7,3%
EPS Revisions
Managers
NameTitle
John R. Chiminski Chairman, President & Chief Executive Officer
Alessandro Maselli Senior Vice President-Global Operations
Wetteny Joseph CFO, Principal Accounting Officer & Senior VP
Jack L. Stahl Lead Independent Director
Rolf Allan Classon Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALENT INC36.85%6 214
JOHNSON & JOHNSON7.28%368 634
NOVARTIS10.80%237 206
PFIZER-3.09%234 841
ROCHE HOLDING LTD.10.93%232 383
MERCK AND COMPANY7.20%211 428